Page 56 - MemoriaBBN-Eng

TECHNOLOGICAL OFFER

maceutical vehicle. An excipient comprises any inert material used in the preparation

of a form for dosage. A particular kind of excipients is the transfection agents, which
improves the vector properties. The administration of these compounds can be oral,

parenteral, intravenous, intramuscular subcutaneous, intra-duodenal, etc.

• MAGNETIC-LUMINESCENTPARTICLESFORBIO-MEDICALSAPPLICATIONS

Spanish Patent ES 2367959 B1

The authors have developed a system of magnetic-luminescent particles, with a size
inferior to three microns, and the procedure for its preparation. They can present a lu-

minescence of high efficacy in the near infrared spectrum and in the whole visible one,

from 400 to 1500 nm (blue to near IR). The luminescence can last until one week after
the synthesis. The particle surface can be modified by linking molecules or functional

groups, forming a biocompatible coating. In vitro assays have shown that both types

of particle functionalized or not, are not cytotoxic. These studies also shown that these
particles can be efficiently internalized into the cells, through interaction with specific

membrane receptors. The viability rate of the cells, in the presence of these particles,
was 95-98%, after 72 hours in culture. This invention also provides pharmaceutical

formulations including active biological molecules in these particles.

• MESENCHYMALCELLSANDACOMPOUNDMEMBRANEFORTHE
TREATMENT OF OSTEOCHONDRAL LESIONS

Spanish Patent ES2380674 B1

The present invention provides and efficient product for the cellular therapy of articular
cartilage lesions, which is prepared in vitro, and is based in autologous adult mesenchymal

stem cells and a biomaterial with a new fibrillar organization in the shape of a compound
membrane.

Thanks to this product, in the chondro-osteo-articular lesion a regenerative tissue is formed

equal to the adjacent cartilage in the three cartilaginous strata, and equal to the subchondral

bone in the organization of the cells, and in the amount and quality of either the cartilagi-
nous or the bone surrounding matrix. The generated tissue integrates in a permanent way

in the receptor tissue, and, besides, it is functional regarding its response to loads.

The authors of the present invention have demonstrated that this product allows the forma-
tion of cartilage in a natural way, therefore the new tissue is formed de novo, and integrates

in the treated tissue, allowing a stable, long-lasting, and functional regeneration. That is, the

product allows a intra-tissue, rather than a lesion, repair.

Therefore, a first aspect of the present invention refers to a composition comprising mes-
enchymal stem cells and a compound membrane. The term “compound” make reference to

that the membrane presents at least two layers with different structure. A second aspect of
13
the present invention refers to the use of the pharmaceutical composition to prepare a drug 20
for the treatment of a cartilage lesion, for the regeneration of the cartilage, for the treatment T
R
of a bone lesion, for the regeneration of the bone, for the treatment of a osteochondral le- PO
sion, for the treatment of osteoarthritis, for the regeneration of the cartilage. A third aspect E
L R
of the present invention refers to an obtaining method for the pharmaceutical composition A
NU
of the invention.
N
A
/
BN
• MODIFIEDOLIGONUCLEOTIDESASREGULATORSOFGENEEXPRESSION
B
R-
Spanish Patent ES2372237B1
BE
CI
In the present invention, new siRNA compounds are described, which are more stable
and efficient in inhibiting gene expression. The synthesis procedures for oligoribo-
56
nucleotides containing chemical groups are also described.